Increased CD16a (FcγRIIIA) Expression in The Tumor Microenvironment of Atypical Neurofibromatous Neoplasms of Uncertain Biologic Potential May Be Associated with Progression from Neurofibromas to Atypical Neurofibromas

Min‐Kyung Yeo, Yeong Jun Koh, Jong‐Il Park, Kyung‐Hee KimJournal of Personalized Medicine 2023 · DOI

TL;DR

This study investigates the role of CD16a, an immune receptor, in the progression of neurofibromas (NFs) to atypical neurofibromatous neoplasms of uncertain biologic potential (ANNUBPs). Researchers found that CD16a expression is significantly elevated in ANNUBPs compared to NFs and malignant tumors, suggesting its involvement in the transition from benign to potentially malignant peripheral nerve sheath tumors.

What Problem Does This Paper Address?

Neurofibromas (NFs) are common benign peripheral nerve sheath tumors that can cause significant functional impairment and disfigurement due to their infiltrative nature. While some NFs can progress to more aggressive forms like atypical neurofibromatous neoplasms of uncertain biologic potential (ANNUBPs) and eventually malignant peripheral nerve sheath tumors (MPNSTs), the underlying mechanisms driving this progression are not fully understood. Specifically, the role of the tumor microenvironment (TME), including immune cells, in this process remains an area needing further exploration. This paper aims to shed light on how specific immune markers, particularly CD16a, might be involved in the transition from NFs to ANNUBPs.

Methods

The researchers employed immunohistochemical staining to evaluate the expression levels of several markers, including CD16a, CD16b, CD68, TREM2, Galectin-3, S-100, and SOX10, in tissue samples from 38 patients. These samples were categorized into three groups: neurofibroma (NF, n=18), atypical neurofibromatous neoplasm of uncertain biologic potential (ANNUBP, n=14), and malignant peripheral nerve sheath tumor (MPNST, n=6). Dual immunohistochemical staining was used to visualize the co-localization of specific proteins, such as CD16a and CD68, within the TME. Quantitative analysis of staining intensity was performed using specialized software, and statistical analyses (Kruskal-Wallis H test, Bonferroni correction, Spearman's correlations, Mann-Whitney U test, and Pearson's chi-squared test) were used to compare expression levels and correlate them with clinicopathological factors.

Datasets

The study utilized a dataset of 38 human tissue samples obtained from patients who underwent surgical resection of neurogenic tumors. These samples were collected retrospectively from Chungnam National University Hospital and Chungnam National University Sejong Hospital between 2002 and 2022. The dataset comprised:

  • 18 cases of Neurofibroma (NF)
  • 14 cases of Atypical Neurofibromatous Neoplasm of Uncertain Biologic Potential (ANNUBP)
  • 6 cases of Malignant Peripheral Nerve Sheath Tumor (MPNST) arising in neurofibroma.

No new benchmarks or datasets were introduced; the study relied on existing patient samples.

Key Insights and Ideas

  • CD16a as a potential marker for NF progression: The most striking finding is the significantly elevated expression of CD16a in ANNUBPs compared to both NFs and MPNSTs. This suggests that CD16a might play a crucial role in the transition from a benign NF to a more concerning ANNUBP.
  • Immune cell involvement in tumor progression: The study highlights the importance of the TME, particularly immune cells, in NF progression. The co-localization of CD16a and CD68 (a macrophage marker) in TME immune cells of ANNUBPs points towards an active immune response contributing to the tumor's altered biological potential.
  • CD16a's role in immunomodulation: The researchers hypothesize that CD16a's overexpression in ANNUBPs could be involved in modulating the local immune response, potentially facilitating tumor infiltration and growth. This suggests a shift in the immune landscape as NFs progress.
  • Inverse relationship with malignancy: Interestingly, CD16a expression decreased as the tumors became more malignant (from ANNUBP to MPNST), implying its specific role in the earlier stages of progression rather than in established aggressive tumors.

Key Results

  • CD16a and CD16b significantly elevated in ANNUBPs: Expression levels of CD16a and CD16b were significantly higher in ANNUBPs compared to NFs and MPNSTs.
  • CD68 and Galectin-3 also higher in ANNUBPs: Expression of CD68 and Galectin-3 was also found to be higher in ANNUBPs than in MPNSTs.
  • Overlapping CD16a and CD68 expression: Dual staining revealed an overlapping pattern of CD16a and CD68 expression in the TME immune cells of ANNUBPs, suggesting a role for CD16a-expressing macrophages.
  • CD16a expression decreased with malignant progression: While CD16a was elevated in ANNUBPs, its expression was lower in MPNSTs, indicating a potential role in early-stage progression.
  • No significant correlation with survival: Univariate Cox proportional hazard regression analysis showed no significant association between CD16a expression (or other markers studied) and disease-free survival or overall survival in the analyzed patient groups.

Limitations and Future Work

  • Retrospective study design: The study is retrospective, which inherently limits the ability to establish causality.
  • Limited sample size for MPNST: The MPNST group had a relatively small sample size (n=6), which might affect the statistical power for comparisons involving this group.
  • Need for functional studies: The paper acknowledges that further studies are needed to explore the functional role of CD16a in immunomodulation and its direct impact on NF growth. This could involve in vitro experiments or more detailed in vivo models.
  • Clarifying ANNUBP definition: The authors note that the clinicopathological and genetic definitions of ANNUBPs still require further refinement, which could impact future research in this area.
  • Therapeutic implications: The authors suggest that a better understanding of CD16a's role could pave the way for developing novel therapeutic approaches for NF progression.

Summary updated

Abstract

Neurofibroma (NF) is a benign tumor in the peripheral nervous system, but it can infiltrate around structures and cause functional impairment and disfigurement. We incidentally found that the expression of CD16a (Fc gamma receptor IIIA) was increased in NFs compared to in non-neoplastic nerves and hypothesized that CD16 could be relevant to NF progression. We evaluated the expressions of CD16a, CD16b, CD68, TREM2, Galectin-3, S-100, and SOX10 in 38 cases of neurogenic tumors (NF, n = 18; atypical neurofibromatous neoplasm of uncertain biologic potential (ANNUBP), n = 14; and malignant peripheral nerve sheath tumor (MPNST), n = 6) by immunohistochemical staining. In the tumor microenvironment (TME) of the ANNUBPs, CD16a and CD16b expression levels had increased more than in the NFs or MPNSTs. CD68 and Galectin-3 expression levels in the ANNUBPs were higher than in the MPNSTs. Dual immunohistochemical staining showed an overlapping pattern for CD16a and CD68 in TME immune cells. Increased CD16a expression was detected in the ANNUBPs compared to the NFs but decreased with malignant progression. The CD16a overexpression with CD68 positivity in the ANNUBPs potentially reflects that the TME immune modulation could be associated with NF progression to an ANNUBP. Further studies should explore the role of CD16a in immunomodulation for accelerating NF growth.
BibTeX
@article{yeo2023increased,
  author = {Min‐Kyung Yeo and Yeong Jun Koh and Jong‐Il Park and Kyung‐Hee Kim},
  title = {{Increased CD16a (FcγRIIIA) Expression in The Tumor Microenvironment of Atypical Neurofibromatous Neoplasms of Uncertain Biologic Potential May Be Associated with Progression from Neurofibromas to Atypical Neurofibromas}},
  journal = {Journal of Personalized Medicine},
  year = {2023},
  doi = {10.3390/jpm13121720},
}
Figure